Jul 11: Hyderabad-based drug maker Dr. Reddy’s Laboratories Ltd on Wednesday announced the launch of its Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) Tablets, in the US market, approved by the US Food and Drug Administration (USFDA).
The Plaquenil brand and generic had US sales of approximately $215 million MAT for the most recent twelve months ending in May 2018 according to IMS Health.
“Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500,” the company said.
Plaquenil is a trademark of Concordia International Corp.